Cardiogenic shock primary prevention: Difference between revisions

Jump to navigation Jump to search
No edit summary
Line 4: Line 4:


==Overview==
==Overview==
Cardiogenic shock is considered an [[emergency]] and irrespectively to the [[therapeutic]] approach, the target goal of any [[therapy]] is prompt [[revascularization]] of [[ischemic myocardium]]. This should be achieved in the shortest timespan possible. There are two major categories of treatment for cardiogenic shock, the ''medical/conservative approach'' and the ''interventional approach''. The ideal [[therapy|treatment]] combines both mechanisms, in which medical therapy, after restored filling pressures, allows [[hemodynamic|hemodynamical]] stabilization of the patient, until interventional methods, that contribute to the reversal of the process leading to the [[shock]] state, may performed. The interventional approach may include [[PCI]] or [[coronary artery bypass graft surgery]] ([[CABG]]) and in both techniques the goal is not only reperfusion of the occluded [[coronary artery]], but also prevention of [[coronary artery|vessel]] reoclusion. If there is no access to a [[cardiac catheterization]] facility, nor the possibility of transferring the patient to one within 90 minutes, then immediately [[thrombolytic therapy]] should be considered.<ref name="NgYeghiazarians2011">{{cite journal|last1=Ng|first1=R.|last2=Yeghiazarians|first2=Y.|title=Post Myocardial Infarction Cardiogenic Shock: A Review of Current Therapies|journal=Journal of Intensive Care Medicine|volume=28|issue=3|year=2011|pages=151–165|issn=0885-0666|doi=10.1177/0885066611411407}}</ref> Other important factors to increase the chances of a better [[outcome]] are: [[mechanical ventilation]], in order to improve [[tissue]] [[oxygenation]], and close monitoring of the [[therapeutic]] dosages, particularly of [[vasoactive]] drugs, since these have been associated with excess [[mortality]] due to [[toxicity]] effects.<ref name="pmid17387132">{{cite journal| author=TRIUMPH Investigators. Alexander JH, Reynolds HR, Stebbins AL, Dzavik V, Harrington RA et al.| title=Effect of tilarginine acetate in patients with acute myocardial infarction and cardiogenic shock: the TRIUMPH randomized controlled trial. | journal=JAMA | year= 2007 | volume= 297 | issue= 15 | pages= 1657-66 | pmid=17387132 | doi=10.1001/jama.297.15.joc70035 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17387132  }} </ref><ref name="pmid16505643">{{cite journal| author=Sakr Y, Reinhart K, Vincent JL, Sprung CL, Moreno R, Ranieri VM et al.| title=Does dopamine administration in shock influence outcome? Results of the Sepsis Occurrence in Acutely Ill Patients (SOAP) Study. | journal=Crit Care Med | year= 2006 | volume= 34 | issue= 3 | pages= 589-97 | pmid=16505643 | doi=10.1097/01.CCM.0000201896.45809.E3 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16505643  }} </ref> Also, it is recommended [[invasive]] [[hemodynamic]] monitoring, in order to monitor and guide the effects of the [[therapy]] as well as the overall status of the patient. The success of [[reperfusion]] is usually suggested by the relief of [[symptoms]], restoration of [[hemodynamic]] parameters and electrical stability, as well as the reduction of at least 50% in the [[ST-segment]] on the [[EKG]], in the case of a [[STEMI]].<ref name="NgYeghiazarians2011">{{cite journal|last1=Ng|first1=R.|last2=Yeghiazarians|first2=Y.|title=Post Myocardial Infarction Cardiogenic Shock: A Review of Current Therapies|journal=Journal of Intensive Care Medicine|volume=28|issue=3|year=2011|pages=151–165|issn=0885-0666|doi=10.1177/0885066611411407}}</ref><ref>{{cite book | last = Hochman | first = Judith | title = Cardiogenic shock | publisher = Wiley-Blackwell | location = Chichester, West Sussex, UK Hoboken, NJ | year = 2009 | isbn = 9781405179263 }}</ref>
Available data indicate that the development of shock after hospital admission with acute MI is as common as cardiogenic shock on presentation. Because of the > 50% mortality associated with both of these conditions, the most favorable means of making an impact on shock mortality is to prevent its development. Therefore, effective therapy for shock must include a prevention strategy. In the GUSTO study, 70% of patients who developed cardiogenic shock after admission were Killip class I on admission, and of the remaining patients most were in Killip class 11 with only mild heart failure.? For this reason, other clinical clues must be used to recognize patients at high risk for developing shock. The development of tachycardia or evidence ofperiphera1 vasoconstriction are early clinical signs ofthe "preshock" state. Data from the Secondary Prevention Reinfarction Israel Nifedipine Trial (SPRINT) study") suggest that the presence of diabetes, history of angina, peripheral vascular or cerebrovascular disease, prior MI, and female gender are all risks for development of shock in Killip class I patients with acute infarction. These investigators estimated a 35% probability of developing shock if all six of these factors were present on admission. In addition to these clinical factors obtained from the history and physical examination, diagnostic studies such as early two-dimensional echocardiography may be helpful in evaluating selected patients. In a consecutive series of over 80 patients, Gibson etnl. stratified patients with acute MI into two groups: those with asynergy in the infarct zone only and those with asynergy in the infarct zone plus a remote zone. They found that the latter group had a significantly higher incidence of cardiogenic shock (34 vs. 8%, p = 0.01), as well as higher rates of death, reinfarction, and Killip class progression than patients with asynergy in the infarct zone only. It is likely that all of the above information is helpful in identifying patients with triple-vessel coronary artery disease in an otherwise low-risk clinical group (i.e., patients without heart failure on admission).


==Primary prevention==
==Primary prevention==

Revision as of 17:05, 31 December 2019

Cardiogenic Shock Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Cardiogenic shock from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Cardiogenic shock primary prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Cardiogenic shock primary prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Cardiogenic shock primary prevention

CDC on Cardiogenic shock primary prevention

Cardiogenic shock primary prevention in the news

Blogs on Cardiogenic shock primary prevention

Directions to Hospitals Treating Cardiogenic shock

Risk calculators and risk factors for Cardiogenic shock primary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: João André Alves Silva, M.D. [2] Syed Musadiq Ali M.B.B.S.[3]

Overview

Available data indicate that the development of shock after hospital admission with acute MI is as common as cardiogenic shock on presentation. Because of the > 50% mortality associated with both of these conditions, the most favorable means of making an impact on shock mortality is to prevent its development. Therefore, effective therapy for shock must include a prevention strategy. In the GUSTO study, 70% of patients who developed cardiogenic shock after admission were Killip class I on admission, and of the remaining patients most were in Killip class 11 with only mild heart failure.? For this reason, other clinical clues must be used to recognize patients at high risk for developing shock. The development of tachycardia or evidence ofperiphera1 vasoconstriction are early clinical signs ofthe "preshock" state. Data from the Secondary Prevention Reinfarction Israel Nifedipine Trial (SPRINT) study") suggest that the presence of diabetes, history of angina, peripheral vascular or cerebrovascular disease, prior MI, and female gender are all risks for development of shock in Killip class I patients with acute infarction. These investigators estimated a 35% probability of developing shock if all six of these factors were present on admission. In addition to these clinical factors obtained from the history and physical examination, diagnostic studies such as early two-dimensional echocardiography may be helpful in evaluating selected patients. In a consecutive series of over 80 patients, Gibson etnl. stratified patients with acute MI into two groups: those with asynergy in the infarct zone only and those with asynergy in the infarct zone plus a remote zone. They found that the latter group had a significantly higher incidence of cardiogenic shock (34 vs. 8%, p = 0.01), as well as higher rates of death, reinfarction, and Killip class progression than patients with asynergy in the infarct zone only. It is likely that all of the above information is helpful in identifying patients with triple-vessel coronary artery disease in an otherwise low-risk clinical group (i.e., patients without heart failure on admission).

Primary prevention

Attending to the definition of primary prevention, namely the group of measures that aim to avoid the development of a disease state (preventive measures) and considering the fact that left ventricular failure following acute MI is the most common cause of cardiogenic shock, these patients should undergo primary prevention of myocardial infarction.[1]

References

  1. Eckel RH, Jakicic JM, Ard JD, Hubbard VS, de Jesus JM, Lee IM; et al. (2013). "2013 AHA/ACC Guideline on Lifestyle Management to Reduce Cardiovascular Risk: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines". Circulation. doi:10.1161/01.cir.0000437740.48606.d1. PMID 24222015.


Template:WikiDoc Sources